



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PW0787

Cat. No.: HY-138639
CAS No.: 2624131-45-7
Molecular Formula: C₂₃H₂₀F₄N₄O₂
Molecular Weight: 460.42
Target: GPR52
Pathway: GPCR/G Protein
Storage: 4°C, protect from light
 * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (108.60 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.1719 mL	10.8596 mL	21.7193 mL
		5 mM		0.4344 mL	2.1719 mL	4.3439 mL
		10 mM		0.2172 mL	1.0860 mL	2.1719 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	PW0787 is a potent, selective, orally active, and brain-penetrant GPR52 agonist (EC ₅₀ =135 nM). PW0787 suppresses psychostimulant behavior ^[1] .
IC ₅₀ & Target	EC ₅₀ : 135 nM (GPR52) ^[1]
In Vivo	PW0787 (0.3, 1, 3, or 10 mg/kg; IP) displays antipsychotic-like activity by significantly inhibiting amphetamine-induced hyperlocomotor behavior in mice ^[1] . PW0787 is evaluated in rats after a single dose of 20 mg/kg by oral (PO) or 10 mg/kg by intravenous (IV) administration. PW0787 has excellent plasma exposure after PO (AUC _{0-inf} = 13,749 ng•h/mL) and IV dosing (AUC _{0-inf} =9030 ng•h/mL), as well as high maximum serum concentration following PO (C _{max} =3407 ng/mL) and IV administration (C _{max} =6726 ng/mL). Additionally, PW0787 displays good volume of plasma distribution (V _{ss} =1.5 L/kg) and acceptable plasma clearance (CL=1.1

L/h/kg) after 10 mg/kg IV. Excellent oral bioavailability (F) with the value of 76% is observed^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naïve male C57/BL6 mice weighing between 24 and 31 g
Dosage:	0.3, 1, 3, or 10 mg/kg (dissolved in 0.9% saline containing 20% HP- β -CD with a final pH of the solution adjusted to 7.4)
Administration:	IP
Result:	Suppressed amphetamine (AMPH)-induced horizontal activity at both 3 mg/kg and 10 mg/kg doses.

REFERENCES

[1]. Wang P, et al. Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior. J Med Chem. 2020;63(22):13951-13972.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA